View source for CR:DOI:2483a49cfbd2a70760de3abb1cb8a780

{{#scite:
 |reference=maertens2016is
 |type=journal-article
 |title=Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial
 |author=Johan A Maertens;Issam I Raad;Kieren A Marr;Thomas F Patterson;Dimitrios P Kontoyiannis;Oliver A Cornely;Eric J Bow;Galia Rahav;Dionysios Neofytos;Mickael Aoun;John W Baddley;Michael Giladi;Werner J Heinz;Raoul Herbrecht;William Hope;Meinolf Karthaus;Dong-Gun Lee;Olivier Lortholary;Vicki A Morrison;Ilana Oren;Dominik Selleslag;Shmuel Shoham;George R Thompson;Misun Lee;Rochelle M Maher;Anne-Hortense Schmitt-Hoffmann;Bernhardt Zeiher;Andrew J Ullmann|+sep=;
 |journal=The Lancet
 |publisher=Elsevier BV
 |year=2016
 |volume=387
 |issue=10020
 |pages=760-769
 |doi=10.1016/s0140-6736(15)01159-9
 |issn=0140-6736
 |retrieved-from=https://dx.doi.org/
 |retrieved-on=2024-10-01
 |@show=true
}}